Skip to content

Anorexia iN Cancer Patients: ANCHOR

Anorexia iN Cancer Patients: Assessment of the Gut HORmone and Cytokine Profile and Body Composition, and the Impact of Dietetic Support in Patients With Gastrointestinal Cancer. (ANCHOR Study)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04791254
Acronym
ANCHOR
Enrollment
450
Registered
2021-03-10
Start date
2021-07-15
Completion date
2026-04-30
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Oesophageal Cancer

Brief summary

The rationale for this study is to prospectively investigate the outcomes of patients undergoing standard dietetic interventions alongside treatment for their advanced gastrointestinal cancers, and to further characterise the relationship with body composition. A number of patients will be enrolled in a sub-study investigating the neuronal-enteroendocrine-hypothalamic axis. Gut hormone study. Our hypothesis is that proinflammatory cytokines produced by the tumour can not only affect appetite directly through the vagal and the central melanocortin system but also indirectly though the enhanced EEC activity; either through increased number or increased function. In this study, the investigators will explore and compare the pattern and levels (pre-prandial and post prandial) of the pro-inflammatory cytokines and gut hormones between stage-standardised anorexic and non-anorexic cancer patients and age-matched healthy controls.

Detailed description

Poor nutritional status contributes significantly to poor outcomes in patients with upper GI cancers, in some patients, directly leading to death. Poor fitness, in terms of reduced muscle mass (sarcopenia) or physical performance, is associated with higher treatment toxicity and poor treatment outcomes. However the relationship between different markers of nutritional status and body composition with fitness is not fully understood. It is also not known what impact dietetic interventions have on the reduced survival seen in patients with weight loss at baseline. Finally, the underlying interaction between the neuronal-enteroendocrine-hypothalamic axis that regulates appetite is poorly understood but believed to be impaired in patients with upper GI cancers because of a number of altered mechanisms. Therefore the rationale for this study is to prospectively investigate the outcomes of patients undergoing standard dietetic interventions alongside treatment for their advanced gastrointestinal cancers, and to further characterise the relationship with body composition. A number of patients will be enrolled in a sub-study investigating the neuronal-enteroendocrine-hypothalamic axis. The hypothesis is that proinflammatory cytokines produced by the tumour can not only affect appetite directly through the vagal and the central melanocortin system but also indirectly though the enhanced EEC activity; either through increased number or increased function. In this study, the investigators will explore and compare the pattern and levels (pre-prandial and post prandial) of the pro-inflammatory cytokines and gut hormones between stage-standardised anorexic and non-anorexic cancer patients and age-matched healthy controls.

Interventions

None listed

Sponsors

University of Manchester
CollaboratorOTHER
Manchester Metropolitan University
CollaboratorOTHER
The Christie NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Inclusion criteria: Cohort A 1. Patients with stage IV gastric or GOJ adenocarcinoma or locally advanced non-resectable adenocarcinoma 2. Histologically proven adenocarcinoma, squamous cell carcinoma or poorly differentiated carcinoma 3. Patients should be chemotherapy or immune therapy naïve (for their current diagnosis). 4. Patient must be 18 years of age or above. 5. Patient must be able to understand the study information given to them and be willing to give consent for trial participation. 6. Patients should be commencing a course of palliative chemotherapy treatment with the upper GI team at the Christie Hospital In addition the above patients enrolled in cohort B must meet the following criteria Inclusion criteria: Cohort B 1\. Be physically able to perform moderate exercise (to their own tolerance) on a stationary bicycle or treadmill In addition to the above patients in cohort C must meet the following criteria Inclusion Criteria: Cohort C 1. Histologically proven adenocarcinoma or poorly differentiated carcinoma 2. Patients should be chemotherapy or immune therapy naïve. 3. Patients must be able and willing to fast for 8-10 hours. 4 5.1 Patients in the anorexic group must have completed the FAACT AC/S questionnaire and scored ≤24 in total score and ≤ 2 in the appetite specific question. 5.2 For inclusion in the non-anorexic group patients must have completed the FAACT AC/S questionnaire; the total score should be \> 37 and ≥3 for the appetite specific question. Inclusion criteria: Cohort D - healthy controls 1. Participants must be 18 years of age or above. 2. Participants must be able and willing to fast for 8-10 hours. 3. Participants must be able to understand the study information given to them and be willing to give consent for trial participation. 4. Participants must have completed the FAACT AC/S questionnaire and scored ≤24 in total score and ≤ 2 in the appetite specific question, for the anorexic group. For inclusion in the non-anorexic group the total score should be \> 37 and ≥3 for the appetite specific question.

Exclusion criteria

* Participants are excluded from the study if any of the following criteria apply:

Design outcomes

Primary

MeasureTime frameDescription
Survival outcomes in patients with advanced upper gastrointestinal cancers receiving dietetic interventions.Through study completion, median expected overall survival < 1 year.Progression free and overall survival from diagnosis.
Differences in patterns of plasma gut hormone and cytokine levels as measured by ELISA between study participants.3 months from completion of data collectionPlasma gut hormones and cytokine levels as measured via ELISA including, ghrelin, insulin, GLP-1, PYY, pancreatic polypeptide, GIP, CHromogranin A, CCK. The following cytokines will be included. IL-1, IL-6, TNF-α

Secondary

MeasureTime frame
Correlation between hormonal and cytokine profile and body composition as measured by bioelectrical impedance analysis and CT measured muscle mass (for patients only) and density.Within 6 months of completion of data collection
Correlation between nutritional status, body composition and physical fitnessWithin 6 months of completion of data collection

Countries

United Kingdom

Contacts

Primary ContactAlexandra Lewis
alexandra.lewis12@nhs.net+44 161 918 7887
Backup ContactKate Armitage
kate.armitage3@nhs.net+44 161 918 7887

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026